Keyphrases
Acute Coronary Syndrome
100%
Acute Myocardial Infarction
26%
Anticoagulation
20%
Antiplatelet Therapy
23%
Antithrombotic Therapy
49%
Arterial Thrombosis
21%
Aspirin
30%
Atrial Fibrillation
70%
Bleeding
42%
Bleeding Risk
50%
Cardiovascular Disease
16%
Cardiovascular Risk
17%
Clinical Outcomes
27%
Clopidogrel
17%
Coagulation
17%
Confidence Interval
17%
COVID-19
43%
Dual Antiplatelet Therapy
50%
Endogenous Fibrinolysis
84%
Fibrinolysis
53%
Global Thrombosis Test
34%
High Shear
21%
Intensive Care Unit
18%
Lysis Time
24%
Major Adverse Cardiovascular Events
18%
Meta-analysis
47%
Myocardial Infarction
25%
Myocardial Infarction Patients
23%
Occlusion Time
23%
P2Y12 Inhibitors
32%
Percutaneous Coronary Intervention
63%
Platelet Function Tests
26%
Platelet Reactivity
39%
Platelet Thrombus
16%
Primary Percutaneous Coronary Intervention
26%
Prothrombotic Status
34%
Randomized Controlled Trial
17%
Rivaroxaban
26%
Spontaneous Reperfusion
19%
ST-elevation Myocardial Infarction (STEMI)
76%
Systematic Meta-analysis
20%
Thrombolysis
19%
Thromboprophylaxis
17%
Thrombosis
63%
Thrombotic
27%
Thrombotic Complications
19%
Thrombotic Events
17%
Thrombus
35%
Thrombus Formation
33%
Ticagrelor
35%
Medicine and Dentistry
Acetylsalicylic Acid
20%
Acute Coronary Syndrome
55%
Acute Heart Infarction
26%
Anticoagulation
35%
Antiplatelet
48%
Antiplatelet Drug
13%
Antithrombotic
73%
Antithrombotic Therapy
28%
Apoplexy
24%
Artery Thrombosis
23%
Atrial Fibrillation
47%
Biological Marker
15%
Bleeding
47%
Blood Clot Lysis
19%
Blood Clotting
26%
Blood Stasis
15%
Cardiology
16%
Cardiovascular Disease
37%
Cardiovascular Risk
17%
Cardiovascular System
43%
Coronary Artery
16%
Coronary Artery Disease
40%
COVID-19
34%
Disease
15%
Drug Therapy
33%
Fibrinolysis
80%
Fibrinolytic Factor
12%
Function Test
21%
Heart Rhythm
13%
Infarction
12%
Intensive Care Unit
17%
Meta-Analysis
37%
Morphine
13%
Myocardial Infarction
40%
Out of Hospital Cardiac Arrest
13%
Percutaneous Coronary Intervention
48%
Platelet
33%
Platelet Reactivity
31%
Prevalence
14%
Primary Percutaneous Coronary Intervention
26%
Randomized Controlled Trial
12%
ST Segment Elevation Myocardial Infarction
44%
Systematic Review
27%
Thrombin
21%
Thrombocyte Function
32%
Thromboembolism
13%
Thromboprophylaxis
12%
Thrombosis
94%
Thrombus
33%
Venous Thromboembolism
13%
Pharmacology, Toxicology and Pharmaceutical Science
Acetylsalicylic Acid
28%
Acute Coronary Syndrome
84%
Acute Heart Infarction
17%
Adverse Outcome
9%
Anticoagulant Agent
88%
Antiplatelet
86%
Antithrombocytic Agent
14%
Antithrombotic Therapy
13%
Antivitamin K
12%
Apixaban
10%
Artery Thrombosis
24%
Atrial Fibrillation
47%
Biological Marker
19%
Bleeding
43%
Blood Stasis
12%
Brain Ischemia
10%
Cardiovascular Disease
44%
Cardiovascular Risk
22%
Cerebrovascular Accident
24%
Clopidogrel
16%
Combination Therapy
14%
Coronary Artery Disease
38%
Coronavirinae
13%
Dabigatran
12%
Disease
26%
Fibrinolytic Agent
43%
Fibrinolytic Factor
13%
Heart Infarction
46%
Heart Muscle Ischemia
10%
Infarction
11%
Monotherapy
12%
Morphine
15%
Non ST Segment Elevation Myocardial Infarction
9%
Out of Hospital Cardiac Arrest
13%
Pharmacodynamics
13%
Pharmacokinetics
12%
Pharmacotherapy
18%
Placebo
14%
Prasugrel
13%
Prevalence
18%
Purinergic P2Y12 Receptor
11%
Randomized Controlled Trial
13%
Rivaroxaban
24%
ST Segment Elevation Myocardial Infarction
59%
Thrombin
24%
Thrombosis
91%
Thrombus
52%
Ticagrelor
28%
Vorapaxar
12%
Warfarin
9%